ADAR1 Capital Management’s Celldex Therapeutics CLDX Stock Holding History

ADAR1 Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.1M	Buy	619,542 +191,726	+45%	+$6.19M	1.06%	19
2026 Q1	$13.6M	Sell	427,816 -218,951	-34%	-$5.97M	0.8%	28
2025 Q4	$17.6M	Buy	646,767 +537,325	+491%	+$14.2M	1.29%	14
2025 Q3	$2.83M	Buy	109,442 +51,976	+90%	+$1.2M	0.27%	65
2025 Q2	$1.17M	Buy	57,466 +42,866	+294%	+$834K	0.18%	75
2025 Q1	$265K	Buy	+14,600	New	+$326K	0.05%	133
2024 Q4	–	Sell	-5,000	Closed	-$170K	–	237
2024 Q3	$170K	Buy	5,000 +4,697	+1,550%	+$179K	0.03%	167
2024 Q2	$11.2K	Buy	+303	New	+$11.4K	﹤0.01%	230

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ADAR1 Capital Management's CLDX Position: Q2 2026 in Review

ADAR1 Capital Management increased its Celldex Therapeutics (CLDX) stake by 45% in Q2 2026, buying an estimated $6.19M and bringing the position to 619,542 shares worth $23.1M. The position accounts for 1.06% of the portfolio, ranked #19.

ADAR1 Capital Management first reported a position in CLDX in Q2 2024 and has held it in 8 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

ADAR1 Capital Management held 619,542 shares of Celldex Therapeutics worth $23.1M as of Q2 2026.
ADAR1 Capital Management bought 191,726 Celldex Therapeutics shares in Q2 2026, an estimated $6.19M.
Celldex Therapeutics made up 1.06% of ADAR1 Capital Management's portfolio in Q2 2026, its #19 holding.
ADAR1 Capital Management first reported a position in Celldex Therapeutics in Q2 2024 and has held it in 8 quarters since.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.